Cantor Fitzgerald Remains a Buy on Amarin (AMRN)

By Austin Angelo

In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Amarin (AMRNResearch Report), with a price target of $35. The company’s shares closed yesterday at $17.43.

Chen wrote:

“We think the peak sales potential of Vascepa is underappreciated. Therefore, upward earnings revisions to levels not reflected in FactSet consensus expectations should drive AMRN shares higher. Valuation Summary We continue to use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $35.”

According to TipRanks.com, Chen is a 4-star analyst with an average return of 9.0% and a 38.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Melinta Therapeutics Inc.

Amarin has an analyst consensus of Strong Buy, with a price target consensus of $30.20.

See today’s analyst top recommended stocks >>

The company has a one-year high of $23.34 and a one-year low of $2.35. Currently, Amarin has an average volume of 7.53M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It’s product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.